19365-01-6

Usage

Uses

Used in Medical Applications:
1-Methyl-3-hydroxypyrid-2-one is used as a therapeutic agent for managing iron overload in patients with thalassemia. It serves to bind excess iron, promoting its removal from the body through urination, thus mitigating the risk of complications such as organ damage and heart issues.
Used in Thalassemia Treatment:
In the healthcare industry, 1-Methyl-3-hydroxypyrid-2-one is utilized as a chelating medication for the treatment of iron overload conditions that are prevalent in individuals with thalassemia. Its role in binding and removing excess iron makes it an essential component in the comprehensive care of these patients.
Additionally, deferiprone is often administered in conjunction with other treatments for thalassemia to enhance the overall management strategy. It is available in oral tablet form and is generally well-tolerated by patients, with mild gastrointestinal side effects being the most frequently reported adverse reactions. The effectiveness of deferiprone in treating iron overload has established it as a significant and valuable tool in medical practice for patients affected by thalassemia.

InChI:InChI=1/C6H7NO2/c1-7-4-2-3-5(8)6(7)9/h2-4,8H,1H3

Upstream product

• 16867-04-2 dihydroxypyridine 
• 74-88-4 methyl iodide 
• 84719-32-4 3-Hydroxy-2(1H)-pyridinone 
• 20928-63-6 3-methoxy-1H-pyridin-2-one 
• 497-19-8 sodium carbonate 
• 94475-64-6 3-benzyloxy-2-hydroxypyridine 
• 54955-13-4 3-methoxy-1-methyl-2(1H)-pyridone 
• 94475-65-7 3-(benzyloxy)-1-methylpyridin-2(1H)-one 
• 13472-83-8 2-methoxy-3-hydroxypyridine 

Downstream Products

• 37463-96-0 1-Methyl-3-(phenyl-hydrazono)-piperidin-2-one 
• 79246-92-7 3-hydroxy-1-methylpyridine-2(1H)-thione 
• 169237-39-2 3-(benzyloxy)-1-methyl-4-<(2-thioxothiazoldin-1-yl)carbonyl>-2(1H)-pyridinone 
• 1025989-29-0 benzyl 3-(benzyloxy)-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxylate 
• 169237-38-1 3-benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone 
• 33341-99-0 3-hydroxy-1-methyl-2-piperidinone 
• 35825-12-8 1-Methyl-3-hydroxy-6-morpholinomethyl-2-pyridon 

Relevant academic research and scientific papers

SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE

The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

Alpha-emitting complexes

The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.

3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition

Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date. However, concerns about the pharmacokinetic liabilities of the hydroxamic acid moiety have stimulated rese

ALPHA-EMITTING COMPLEXES

The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.

6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR

The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

Synthesis of oxovanadium complexes and their apoptosis-inducing activity in leukemia cells

Vanadium complexes with different ligands were synthesized and evaluated for antiproliferative activity on U937 cells. The alkyl chain length of the ligands affected the antiproliferative activity, and two complexes - 3b and 4 - exhibited strong activities with IC50 values of 6.02 and 3.90 μM respectively. Annexin V staining and DNA ladder formation indicated that these complexes induced apoptosis in U937 cells.

Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: Novel bidentate ligands for cell- labeling

The synthesis of a range of hydroxypyranones and hydroxypyridinones with potential for the chelation of indium(III) is described. The crystal structures of two of the indium complexes are presented. The distribution coefficients of the ligands and the corresponding iron(III), gallium(III), and indium(III) complexes are reported. Good linear relationships between the distribution coefficients of the iron and gallium complexes and iron and indium complexes were obtained. In contrast a nonlinear relationship was obtained between the distribution coefficient of the free ligand and the distribution coefficient of the three groups of complexes. This latter relationship was used to identify compounds with optimal cell labeling properties. Two such compounds both 6-(alkoxymethyl)-3-hydroxy-4H-pyran-4- ones have been compared with tropolone for their ability to label human leucocytes with 111In. The leucocyte labeling efficiencies of the selected ligands were greater and the in-vitro plasma stabilities were similar to that of 111In-tropolonate. These results suggest that the new bidentate ligands may offer advantages over those currently used for cell-labeling.

Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, iron(III)-chelating properties, and biological activity

The synthesis of a range of novel bidentate and hexadentate ligands containing the chelating moiety 3-hydroxy-2(1H)-pyridinone is described. The pK(a) values of the ligands and the stability constants of their iron(III) complexes have been determined. The stability constant of the iron(III) complex of one of the hexadentate ligands is comparable to that of desferrioxamine B. The distribution coefficients of the ligands and their iron(III) complexes were also determined. One of the novel hexadentate compounds has been shown to markedly enhance iron(III) excretion from both hepatocytes and iron-overloaded mice.

New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones

The major diseases of iron metabolism are iron deficiency anaemia, which could be treated using Fe2+ or Fe3+ salt supplements, and iron overload, which could arise either from an increased gastrointestinal absorption of iron or from recurrent blood transfusions. While the former form of iron overload could be treated by phlebotomy the latter requires the use of a chelator. Desferrioxamine is the only clinically available chelator for the treatment of iron overload but its use worldwide is limited because it is expensive and orally inactive. Several α-ketohydroxy heteroaromatic chelators have been synthesised and tested for their iron binding properties at physiological pH. The synthetic route involves the benzylation of the hydroxyl group of maltol using benzyl chloride, the conversion of the benzylated maltol to the 1-alkyl benzylated pyridine derivative by introducing the corresponding alkylamine in alkaline conditions and the cleavage of the benzyl group in acid to form the 1-alkyl-2-methyl-3-hydroxypyrid-4-one. All the chelators are water soluble and stable at a wide range of pH, forming stable, water soluble, coloured iron complexes with a molar ratio of approximately 3 chelator:1 iron at pH 7.4 and lower molar ratio of chelators to iron complexes at acidic pH. When the 1-methyl, 1-ethyl and 1-propyl, -2-methyl-3-hydroxypyrid-4-ones were mixed at pH 7.4 with transferrin, ferritin and haemosiderin substantial amounts of iron were released. The low cost of synthesis, the strong iron binding properties of these chelators and their other in vitro and in vivo iron mobilising effects increase the prospects of their use in many aspects of iron metabolism and the possible treatment of related diseases particularly iron overload.